Leap Therapeutics, Inc. (LPTX) Stock Analysis & Investment Frameworks
Leap Therapeutics, Inc. (LPTX) stock analysis on Invetso. Review Leap Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Leap Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Leap Therapeutics, Inc. Key Financial Metrics
- Market Cap: $31.86M
- Revenue: $N/A
- P/E Ratio: 6.41
- ROE: 23.83%
- ROIC: -12.58%
- Dividend Yield: N/A
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.